普洛藥業(000739.SZ):一年多年前就開始全產業鏈佈局多肽領域,製劑研發預計明年二季度會進入臨牀
格隆匯10月20日丨普洛藥業(000739.SZ)於2023年10月19日接受投資者調研,就“多肽領域佈局,如何看待公司在這方面的競爭力?”,公司回覆稱,公司一年多年前就開始全產業鏈佈局多肽領域,前期我們佈局了側鏈、保護氨基氨酸和中間體,主要是CDMO業務;製劑研發預計明年二季度會進入臨牀;原料藥已完成了研發,即將開始建設固相合成連續合成的生產線;我們也會佈局生物法司美格魯肽產品,生物法可能更具有成本優勢,但是大規模上市預計是司美格魯肽口服制劑上市之後需求量才會更大,注射劑用量較小,我們生物法司美格魯肽佈局主要針對口服司美格魯肽。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.